Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

Paulette Mhawech-Fauceglia, Dan Wang, Damanzoopinder Samrao, Heidi Godoy, Faith Ough, Song Liu, Tanja Pejovic, Shashikant Lele

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalGynecologic oncology
Volume127
Issue number1
DOIs
StatePublished - Oct 1 2012

    Fingerprint

Keywords

  • Disease outcome
  • Immunoexpression
  • Ovarian serous cancer
  • PAX8

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this